MycoTOX Profile — Urinary Mycotoxin Panel (Mosaic Diagnostics)

Ochratoxin A is a chlorinated isocoumarin-phenylalanine mycotoxin produced primarily by Aspergillus ochraceus, Aspergillus carbonarius, and Penicillium verrucosum — moulds prevalent in water-damaged buildings, stored grains, dried fruits, coffee, cocoa, wine, beer, and spices. OTA is a renal tubular nephrotoxin, immunosuppressant, and IARC Group 2B possible human carcinogen absorbed readily from the gastrointestinal tract and bound tightly to serum albumin. Its elimination half-life is prolonged — approximately 35 days in humans — due to enterohepatic recirculation, allowing accumulation with repeated low-level dietary or environmental exposure. A small proportion is excreted unchanged in urine, making urinary OTA a biomarker of recent and accumulated exposure.

Ochratoxin A is the most frequently detected mycotoxin in urinary mycotoxin panels in North American and European populations, reflecting its widespread presence in both the food supply and water-damaged building environments. In functional medicine, elevated urinary OTA is associated with chronic fatigue, immune suppression, renal tubular dysfunction, and neurotoxic symptoms in patients with significant exposure. Urinary OTA detection confirms recent metabolic processing — not necessarily active ongoing exposure — and must be interpreted alongside exposure history (diet, water-damaged building contact) and clinical presentation. Mainstream nephrology and toxicology guidelines do not establish urinary OTA clinical action thresholds; clinical decision thresholds used in functional medicine are proprietary to individual laboratory reference frameworks.

Aflatoxins are difuranocoumarin mycotoxins produced primarily by Aspergillus flavus and Aspergillus parasiticus — ubiquitous storage moulds contaminating maize, peanuts, tree nuts, cottonseed, and spices, particularly under warm and humid conditions. Aflatoxin B1 (AFB1) is the most potent naturally occurring carcinogen known — classified as an IARC Group 1 human carcinogen — activated in the liver by CYP450 enzymes (principally CYP3A4 and CYP1A2) to a reactive epoxide that forms DNA adducts causing TP53 mutations associated with hepatocellular carcinoma. Aflatoxin M1 (AFM1) — the 4-hydroxylated metabolite of AFB1 — is the primary urinary biomarker of dietary AFB1 exposure, excreted in urine within hours of ingestion. AFM1 is also found in the breast milk and urine of dairy animals consuming AFB1-contaminated feed.

Urinary aflatoxin detection — particularly AFM1 — provides direct evidence of recent dietary aflatoxin exposure from contaminated peanut products, corn, tree nuts, or dried spices. Elevated urinary aflatoxins in functional medicine assessments are associated with hepatotoxic risk, immunosuppression, and — at sustained high exposures — hepatocellular carcinoma risk in combination with hepatitis B infection. Exposure source identification is the primary clinical action — dietary review and source elimination are the intervention priorities. Water-damaged building exposure as a source of aflatoxin is less common than dietary exposure in North American populations; food-sourced aflatoxin exposure through contaminated staple grains is predominantly a concern in sub-Saharan Africa, Southeast Asia, and agricultural communities with poor grain storage.

Trichothecenes are a structurally diverse family of sesquiterpenoid mycotoxins produced by multiple fungal genera — Fusarium (producing Type A and B trichothecenes, widespread in grain crops), Stachybotrys chartarum (producing macrocyclic trichothecenes including satratoxins and roridins, associated with water-damaged buildings), and Myrothecium. Their shared mechanism of toxicity is irreversible inhibition of eukaryotic protein synthesis by binding the 60S ribosomal subunit, with additional induction of oxidative stress and apoptosis in rapidly dividing cells — lymphocytes, epithelial cells, and gastrointestinal mucosa are particularly sensitive. Macrocyclic trichothecenes from Stachybotrys are among the most potent protein synthesis inhibitors known and have been implicated in the 'sick building syndrome' complex associated with flooded or water-damaged structures.

Trichothecene detection in urinary mycotoxin panels has distinct interpretive implications depending on the class. Type B trichothecenes — particularly deoxynivalenol (DON, 'vomitoxin') — are widespread dietary contaminants of wheat, barley, and oats consumed by humans, and low-level urinary DON detection in the general population reflects common dietary exposure rather than pathological building mould exposure. Macrocyclic trichothecenes from Stachybotrys (satratoxins, roridins, verrucarin) are not present in the food supply and their detection in urine is a specific indicator of exposure to water-damaged building environments harbouring Stachybotrys chartarum. Elevated macrocyclic trichothecenes in a symptomatic patient are one of the most clinically significant findings in the MycoTOX panel, warranting environmental assessment of the patient's home or workplace. # REVIEWER FLAG: The clinical evidence base for urinary trichothecene measurement as a diagnostic biomarker for Stachybotrys-related building illness is debated in mainstream occupational and environmental medicine — reviewer to confirm appropriate interpretive framing for this platform's practitioner audience.

Zearalenone is a non-steroidal resorcylic acid lactone mycotoxin produced primarily by Fusarium graminearum (and related species) on maize, wheat, barley, sorghum, and other cereal grains under cool and humid post-harvest conditions. Zearalenone is an oestrogen receptor agonist — it binds both ERα and ERβ with high affinity, acting as an endocrine-disrupting xenoestrogen and producing oestrogenic effects in both male and female humans and animals. It is metabolised by intestinal and hepatic carbonyl reductases to alpha-zearalanol (α-ZAL, more oestrogenic) and beta-zearalanol (β-ZAL, less oestrogenic), both of which are measurable in urine.

Elevated urinary zearalenone and metabolites reflect recent dietary exposure from contaminated cereal grains and processed grain products. In functional and integrative medicine, zearalenone is assessed as a xenoestrogen contributor to oestrogen dominance patterns, precocious puberty in girls, subfertility, menstrual irregularity, and reproductive endocrine disruption — clinical concerns arising from its oestrogen receptor agonist activity even at low dietary exposure levels. Male exposure is associated with feminising effects including gynaecomastia and reduced sperm quality at higher exposure concentrations. Exposure source identification — contaminated grain, corn, and processed foods — and dietary modification are the primary clinical interventions. # REVIEWER FLAG: The clinical evidence base for zearalenone as a clinically significant xenoestrogen at levels encountered in Western dietary exposure (as opposed to livestock-level contamination) is debated — reviewer to confirm appropriate interpretive framing.

Fumonisins are linear polyketide mycotoxins produced by Fusarium verticillioides and Fusarium proliferatum — moulds that infect maize (corn) worldwide, particularly in warm and humid growing conditions and during drought stress. Fumonisin B1 (FB1) is the most prevalent and toxicologically significant species. Fumonisins inhibit sphinganine N-acetyltransferase (ceramide synthase), disrupting sphingolipid biosynthesis and producing a toxic accumulation of sphinganine and sphingosine that alters membrane structure and cell signalling. They are classified as IARC Group 2B possible human carcinogens, associated with oesophageal cancer risk in high-exposure geographic regions.

Urinary fumonisin detection reflects recent dietary exposure from maize-based foods — cornmeal, polenta, tortillas, corn chips, corn cereals, popcorn, and corn-fed animal products are the primary dietary sources. In functional medicine assessments, elevated fumonisin exposure is associated with impaired sphingolipid metabolism affecting membrane function and is considered a contributing factor in populations with high corn-based dietary patterns. Geographic and dietary context is the primary interpretive framework — populations with high corn staple intake in fumonisin-endemic regions carry meaningfully higher cumulative exposure risk. In Western populations with moderate corn intake, urinary fumonisin detection is more likely to reflect recent dietary exposure than pathological accumulation.

Gliotoxin is an epipolythiodioxopiperazine (ETP) mycotoxin produced almost exclusively by Aspergillus fumigatus — the primary pathogenic Aspergillus species — as a virulence factor that suppresses host immune defence. Its mechanism involves multiple immunosuppressive actions: inhibition of NADPH oxidase in neutrophils (blocking the oxidative burst), induction of apoptosis in macrophages, T-cell, and B-cell lineages via mitochondrial pathway activation, and inactivation of NF-κB signalling. Gliotoxin is not a dietary mycotoxin — it is not produced by food-contaminating fungi under normal circumstances — making its urinary detection specifically associated with Aspergillus fumigatus exposure or active infection rather than food exposure.

Urinary gliotoxin is the most clinically specific mycotoxin in the MycoTOX panel — its detection suggests active Aspergillus fumigatus colonisation of the respiratory tract, invasive aspergillosis in immunocompromised individuals, or sinopulmonary Aspergillus exposure producing urinary gliotoxin metabolite excretion. In functional medicine contexts, urinary gliotoxin is assessed in patients with chronic sinusitis, chronic cough, unexplained immune suppression, or post-mould-exposure illness syndromes where Aspergillus colonisation is a plausible contributor. Elevated urinary gliotoxin in an immunocompromised patient — transplant recipient, haematological malignancy, HIV — warrants urgent infectious disease evaluation for invasive aspergillosis, which is a life-threatening condition. In immunocompetent patients, elevated urinary gliotoxin more likely reflects colonisation or repeated airway exposure than invasive disease. # REVIEWER FLAG: Urinary gliotoxin as a diagnostic marker for invasive aspergillosis or Aspergillus colonisation has limited mainstream evidence base — reviewer to assess whether clinical framing requires additional caveating regarding diagnostic sensitivity and specificity.

Mycophenolic acid is a secondary metabolite produced by multiple Penicillium species — particularly Penicillium brevicompactum, P. roqueforti, and related species found in water-damaged environments, grain storage, and food production. In the environmental context, mycophenolic acid acts as a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme critical for de novo purine biosynthesis in rapidly dividing cells — selectively suppressing lymphocyte proliferation. It is also the pharmacologically active compound in mycophenolate mofetil (MMF), the immunosuppressant drug. Environmental exposure through food contamination (Penicillium-contaminated cheeses, grains) and water-damaged building air exposure are the non-pharmaceutical sources of urinary mycophenolic acid.

Urinary mycophenolic acid detection in the MycoTOX panel must first exclude pharmaceutical mycophenolate mofetil use before environmental exposure is considered — the drug produces urinary mycophenolic acid at concentrations substantially higher than environmental exposure and would dominate the result. With pharmaceutical use excluded, elevated urinary mycophenolic acid in functional medicine assessments is associated with environmental Penicillium exposure from water-damaged buildings or contaminated food, with immunosuppressive implications from IMPDH inhibition. The clinical significance of low-level environmental urinary mycophenolic acid in immunocompetent individuals — as opposed to therapeutic-range levels from pharmaceutical use — is not established by mainstream evidence. # REVIEWER FLAG: This analyte requires explicit documentation of mycophenolate mofetil use on the requisition form as a mandatory pre-analytic clinical context — reviewer to confirm whether Access Medical Laboratories / Mosaic Diagnostics flags this requirement prominently in their collection documentation.

Citrinin is a polyketide nephrotoxic mycotoxin produced primarily by Penicillium citrinum, Penicillium expansum, Aspergillus citricus, and Monascus purpureus — moulds found in stored grains (barley, wheat, oats, rye), red yeast rice fermentation products, and water-damaged environments. In the body, citrinin is rapidly metabolised to dihydrocitrinin (DHC), which is the predominant form excreted in urine and the preferred urinary biomarker of citrinin exposure. Citrinin is nephrotoxic through mitochondrial membrane disruption and oxidative stress in renal proximal tubular cells, frequently co-occurring with ochratoxin A in food-contaminated grains and exhibiting synergistic nephrotoxicity.

Urinary citrinin/DHC detection reflects recent dietary or environmental citrinin exposure. Dietary sources include contaminated grains, red yeast rice supplements (Monascus purpureus-fermented products contain citrinin as a co-metabolite with monacolin K/lovastatin — a significant concern in patients taking red yeast rice for cholesterol management), and water-damaged building environments. In functional medicine, elevated urinary citrinin alongside ochratoxin A is assessed as a combined nephrotoxic burden. The red yeast rice association is clinically important — practitioners should specifically document red yeast rice supplement use alongside the requisition form, as this is a common and overlooked source of citrinin exposure in supplement-using populations.

Sterigmatocystin is a polyketide mycotoxin produced primarily by Aspergillus versicolor — a prevalent mould in water-damaged buildings, indoor dust, and stored grains — and is the penultimate biosynthetic precursor to aflatoxin B1 in the aflatoxin pathway. Aspergillus versicolor does not complete the biosynthetic conversion to aflatoxin, making sterigmatocystin the end-product accumulating in Aspergillus versicolor-contaminated environments. Like aflatoxin B1, sterigmatocystin is activated by hepatic CYP450 enzymes to a reactive epoxide forming DNA adducts.

Urinary sterigmatocystin is a specific biomarker of Aspergillus versicolor exposure — a mould particularly prevalent in water-damaged buildings, insulation, and damp cellulosic materials. Its detection in functional medicine mycotoxin assessments specifically suggests water-damaged building exposure rather than dietary exposure, making it one of the more environmentally specific mycotoxins in the panel alongside the macrocyclic trichothecenes from Stachybotrys. Elevated urinary sterigmatocystin warrants environmental assessment of the patient's home or workplace for Aspergillus versicolor mould contamination, and is interpreted alongside other building-associated mycotoxins (gliotoxin, macrocyclic trichothecenes) to characterise the nature of mould exposure.

Enniatins (including ENN A, A1, B, B1) and beauvericin are cyclic depsipeptide mycotoxins produced primarily by Fusarium species on cereal crops — particularly wheat, maize, barley, and oats — and represent an emerging class of food safety concern. They act as ionophores, disrupting ion transport across cell membranes, and show cytotoxic, antimicrobial, and insecticidal activity. Enniatins are among the most frequently detected mycotoxins in European cereal surveys but have historically been excluded from routine monitoring due to the absence of established regulatory limits.

Enniatins and beauvericin are emerging dietary mycotoxin exposures primarily from contaminated cereal grains and grain-based processed foods. Their clinical significance in human health at levels typically encountered in Western dietary exposure is not yet established by mainstream toxicological evidence — regulatory agencies have not set maximum residue limits or tolerable daily intakes for these compounds in most jurisdictions. In functional medicine mycotoxin panels, their detection reflects recent grain-based dietary exposure. The interpretive framework is evolving, and practitioners should communicate appropriate scientific uncertainty when discussing these analytes with patients. # REVIEWER FLAG: Enniatins and beauvericin have a limited clinical evidence base for health effects at dietary exposure levels — reviewer to assess whether interpretive claims require additional caveating for this platform.